JP2015504902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504902A5 JP2015504902A5 JP2014553589A JP2014553589A JP2015504902A5 JP 2015504902 A5 JP2015504902 A5 JP 2015504902A5 JP 2014553589 A JP2014553589 A JP 2014553589A JP 2014553589 A JP2014553589 A JP 2014553589A JP 2015504902 A5 JP2015504902 A5 JP 2015504902A5
- Authority
- JP
- Japan
- Prior art keywords
- substituents
- optionally substituted
- substituted
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001424 substituent group Chemical group 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- -1 5-[(3aS, 4S, 6aR) -2-oxohexahydro-1H-thieno [3,4-d] imidazol-4-yl] pentanoyl Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 238000000034 method Methods 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 101150009274 nhr-1 gene Proteins 0.000 claims 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 210000004700 fetal blood Anatomy 0.000 claims 3
- 150000003384 small molecules Chemical class 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 102000000646 Interleukin-3 Human genes 0.000 claims 2
- 108010002386 Interleukin-3 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000036693 Thrombopoietin Human genes 0.000 claims 2
- 108010041111 Thrombopoietin Proteins 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 108700014844 flt3 ligand Proteins 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229940076264 interleukin-3 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical group N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000018240 Bone Marrow Failure disease Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 208000027205 Congenital disease Diseases 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010043395 Thalassaemia sickle cell Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 201000001505 hemoglobinuria Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000016245 inborn errors of metabolism Diseases 0.000 claims 1
- 208000015978 inherited metabolic disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 0 CCCCc1c(c2ccc(*)cc2[n]2)c2nc(*)n1 Chemical compound CCCCc1c(c2ccc(*)cc2[n]2)c2nc(*)n1 0.000 description 1
- XQESRORWDXYILU-UHFFFAOYSA-N CNCCCN1CCCCC1 Chemical compound CNCCCN1CCCCC1 XQESRORWDXYILU-UHFFFAOYSA-N 0.000 description 1
- OBLKGLNRMMXCFW-LJGSYFOKSA-N CN[C@H](CC1)CC[C@@H]1N Chemical compound CN[C@H](CC1)CC[C@@H]1N OBLKGLNRMMXCFW-LJGSYFOKSA-N 0.000 description 1
- SIBCJMZHJZDUNK-UHFFFAOYSA-N COC(c1ccc2c3c(NCCCN4CCCCC4)ncnc3[nH]c2c1)=O Chemical compound COC(c1ccc2c3c(NCCCN4CCCCC4)ncnc3[nH]c2c1)=O SIBCJMZHJZDUNK-UHFFFAOYSA-N 0.000 description 1
- AZXXGVPWWKWGAE-UHFFFAOYSA-N C[n]1nnc(-c2ccc3c4c(NC(CC5)CCC5N)nc(Cc5ccccc5)nc4[nH]c3c2)n1 Chemical compound C[n]1nnc(-c2ccc3c4c(NC(CC5)CCC5N)nc(Cc5ccccc5)nc4[nH]c3c2)n1 AZXXGVPWWKWGAE-UHFFFAOYSA-N 0.000 description 1
- XCHLHUVAENNQGI-UHFFFAOYSA-N C[n]1nnc(-c2ccc3c4c(NCCCN5CCCCC5)ncnc4[nH]c3c2)n1 Chemical compound C[n]1nnc(-c2ccc3c4c(NCCCN5CCCCC5)ncnc4[nH]c3c2)n1 XCHLHUVAENNQGI-UHFFFAOYSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591521P | 2012-01-27 | 2012-01-27 | |
| US61/591,521 | 2012-01-27 | ||
| PCT/CA2013/050052 WO2013110198A1 (en) | 2012-01-27 | 2013-01-25 | Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504902A JP2015504902A (ja) | 2015-02-16 |
| JP2015504902A5 true JP2015504902A5 (https=) | 2016-03-17 |
| JP6250556B2 JP6250556B2 (ja) | 2017-12-20 |
Family
ID=48872865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014553589A Active JP6250556B2 (ja) | 2012-01-27 | 2013-01-25 | ピリミド［４，５−ｂ］インドール誘導体及び造血幹細胞の増殖におけるその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US9409906B2 (https=) |
| EP (1) | EP2807165B1 (https=) |
| JP (1) | JP6250556B2 (https=) |
| KR (1) | KR102098122B1 (https=) |
| CN (1) | CN104144931B (https=) |
| AU (1) | AU2013212457B2 (https=) |
| BR (1) | BR112014018524B1 (https=) |
| CA (1) | CA2862140C (https=) |
| CY (1) | CY1121799T1 (https=) |
| DK (1) | DK2807165T3 (https=) |
| ES (1) | ES2733946T3 (https=) |
| FR (1) | FR26C1003I1 (https=) |
| HR (1) | HRP20191189T1 (https=) |
| HU (1) | HUE044070T4 (https=) |
| IL (1) | IL233587B (https=) |
| LT (2) | LT2807165T (https=) |
| NL (1) | NL301363I2 (https=) |
| NO (1) | NO2026005I1 (https=) |
| NZ (1) | NZ627188A (https=) |
| PL (1) | PL2807165T3 (https=) |
| PT (1) | PT2807165T (https=) |
| RS (1) | RS59002B1 (https=) |
| SG (1) | SG11201404241SA (https=) |
| SI (1) | SI2807165T1 (https=) |
| SM (1) | SMT201900360T1 (https=) |
| TR (1) | TR201909582T4 (https=) |
| WO (1) | WO2013110198A1 (https=) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2807165T (pt) | 2012-01-27 | 2019-07-12 | Univ Montreal | Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas |
| EP2970312B1 (en) | 2013-03-11 | 2017-11-15 | The Regents of The University of Michigan | Bet bromodomain inhibitors and therapeutic methods using the same |
| CA2848575C (en) | 2013-05-17 | 2021-01-26 | Universite De Montreal | Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation |
| US9580430B2 (en) | 2014-02-28 | 2017-02-28 | The Regents Of The University Of Michigan | 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors |
| CA2946446C (en) * | 2014-04-22 | 2020-11-03 | Universite De Montreal | Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells |
| CN107208111B (zh) * | 2014-09-18 | 2021-07-06 | 蒙特利尔大学 | 用于增强病毒基因转移至人造血细胞的化合物和方法 |
| NZ733213A (en) * | 2014-12-31 | 2022-10-28 | Celularity Inc | Natural killer cells and uses thereof |
| US10350245B2 (en) | 2015-01-21 | 2019-07-16 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| EP3303570B1 (en) | 2015-06-05 | 2021-01-20 | Héma-Québec | Methods for culturing and/or differentiating hematopoietic stem cells into progenitors and uses thereof |
| US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
| CN105316293A (zh) * | 2015-09-23 | 2016-02-10 | 广东颐养抗衰老研究院 | 一种体外获得造血干/祖细胞的方法 |
| MY201637A (en) * | 2015-10-15 | 2024-03-06 | Celularity Inc | Natural killer cells and ilc3 cells and uses thereof |
| KR102860636B1 (ko) * | 2015-12-28 | 2025-09-17 | 노파르티스 아게 | 혈색소병증의 치료를 위한 조성물 및 방법 |
| WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
| CN109843304A (zh) * | 2016-05-07 | 2019-06-04 | 细胞结构公司 | 使用自然杀伤细胞治疗急性髓性白血病和多发性骨髓瘤的方法 |
| KR102522572B1 (ko) * | 2016-08-18 | 2023-04-17 | 내셔널 유니버시티 오브 싱가포르 | 조혈 줄기 및 전구 세포의 생성, 증식 및 분화를 위한 치환된 아졸 유도체 |
| JP2019532672A (ja) | 2016-09-28 | 2019-11-14 | ノバルティス アーゲー | 多孔質膜系巨大分子送達システム |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| BR112020006256A2 (pt) | 2017-09-29 | 2020-10-20 | Intellia Therapeutics, Inc. | método in vitro de administração de mrna usando nanopartículas de lipídio |
| IL274291B2 (en) * | 2017-11-03 | 2023-10-01 | Univ Montreal | Compounds and their use in proliferation of stem cells and/or progenitor cells |
| EP3735412B1 (en) * | 2018-01-03 | 2024-02-21 | EdiGene Biotechnology, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders |
| US12011460B2 (en) | 2018-02-20 | 2024-06-18 | Universite De Montreal | Expansion of NK and DC cells in vivo mediating immune response |
| TWI721623B (zh) * | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| KR102329235B1 (ko) * | 2018-11-21 | 2021-11-22 | 한국화학연구원 | Irak4 저해제로서 신규의 삼중고리 화합물 |
| US11697799B2 (en) | 2019-04-15 | 2023-07-11 | Ossium Health, Inc. | System and method for extraction and cryopreservation of bone marrow |
| CN115176005A (zh) | 2019-12-18 | 2022-10-11 | 诺华股份有限公司 | 用于治疗血红蛋白病的组合物和方法 |
| AU2020409437A1 (en) * | 2019-12-18 | 2022-07-14 | Universite De Montreal | Modulators of Cullin 3 adaptor KBTBD4 as anti-cancer compounds |
| US20230094952A1 (en) * | 2019-12-26 | 2023-03-30 | Sumitomo Pharma Co., Ltd. | Method for Culturing Hematopoietic Stem Cells |
| EP4146797A1 (en) | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| WO2021256977A1 (en) * | 2020-06-15 | 2021-12-23 | Subramaniam Agatheeswaran | Novel methods and compounds for protein degradation |
| EP4711444A3 (en) * | 2020-06-25 | 2026-04-29 | Angiocrine Bioscience, Inc. | Endothelial cells for mitigation of chemotherapy-induced toxicity |
| EP4181675A4 (en) | 2020-07-18 | 2024-04-24 | Ossium Health, Inc. | PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION |
| EP4228406A4 (en) | 2020-10-14 | 2024-11-13 | Ossium Health, Inc. | SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION |
| CN117279650A (zh) | 2020-12-18 | 2023-12-22 | 奥瑟姆健康公司 | 细胞治疗方法 |
| WO2022230793A1 (ja) * | 2021-04-26 | 2022-11-03 | 住友ファーマ株式会社 | オキセピン誘導体 |
| WO2022232839A1 (en) | 2021-04-30 | 2022-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for improved production of primary cd34+ cells |
| US20250127809A1 (en) | 2021-06-23 | 2025-04-24 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
| GB202111169D0 (en) | 2021-08-03 | 2021-09-15 | Adaptimmune Ltd | Methods of T cell production |
| CN114736862B (zh) * | 2022-05-18 | 2024-05-28 | 诺航生物技术研究院徐州有限公司 | 一种造血干细胞培养基和造血干细胞的体外扩增方法 |
| CN117164593A (zh) * | 2023-08-31 | 2023-12-05 | 贵州省天然产物研究中心 | 一种嘧啶并吲哚类化合物及其制备方法和应用、抗红白血病药物 |
| US11945818B1 (en) | 2023-09-06 | 2024-04-02 | King Faisal University | Pyrrolo[3,2-c]quinoline compounds as CK2 inhibitors |
| US11964981B1 (en) | 2023-09-18 | 2024-04-23 | King Faisal University | Substituted pyrimido[4,5-b]indoles as CK2 inhibitors |
| CN117229284B (zh) * | 2023-11-10 | 2024-02-06 | 上海泽德曼医药科技有限公司 | 三环稠杂环类化合物、其制备方法及其在医药上的应用 |
| US12012414B1 (en) | 2024-01-04 | 2024-06-18 | King Faisal University | Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1262864A (en) | 1968-03-29 | 1972-02-09 | Glaxo Lab Ltd | Diazacarbazoles |
| FI944602A0 (fi) | 1992-04-03 | 1994-10-03 | Upjohn Co | Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| NZ336659A (en) | 1997-01-08 | 2001-01-26 | Upjohn Co | Pharmaceutically active pyrimido[4,5-b]indoles |
| JP2002529502A (ja) | 1998-11-17 | 2002-09-10 | スミスクライン・ビーチャム・コーポレイション | 血小板減少症の治療法 |
| GC0000177A (en) | 1998-12-17 | 2006-03-29 | Smithkline Beecham | Thrombopoietin mimetics |
| WO2000066585A1 (en) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS |
| AU4692400A (en) | 1999-05-03 | 2000-11-17 | Smithkline Beecham Corporation | Cxcr-4 receptor antagonists - thrombopoietin mimetics |
| EP1213965B1 (en) | 1999-09-10 | 2006-01-18 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| ATE350044T1 (de) | 1999-09-24 | 2007-01-15 | Smithkline Beecham Corp | Thrombopoietinmimetika |
| WO2001034585A1 (en) | 1999-11-05 | 2001-05-17 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
| AU2079901A (en) | 1999-12-06 | 2001-06-12 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
| WO2002049413A2 (en) | 2000-12-19 | 2002-06-27 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| WO2002085343A1 (en) | 2001-03-01 | 2002-10-31 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| AU2002309703A1 (en) * | 2001-05-09 | 2002-11-18 | The University Of Louisville Research Foundation, Inc. | Hematopoietic stem cell chimerism to treat autoimmune disease |
| EP1442039A1 (en) * | 2001-10-31 | 2004-08-04 | Bayer HealthCare AG | Pyrimido (4,5-b) indole derivatives |
| AU2003248630A1 (en) | 2002-06-06 | 2003-12-22 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
| EP1581527A4 (en) | 2002-12-13 | 2006-11-22 | Smithkline Beecham Corp | MIMETICS OF THROMBOPOIETINE |
| AU2003300522A1 (en) | 2002-12-27 | 2004-07-22 | Bayer Healthcare Ag | 4-phenyl-pyrimido (4,5-b) indole derivatives |
| CA2565581C (en) | 2003-05-02 | 2014-07-08 | Insception Bioscience, Inc. | Apparatus and methods for amplification of blood stem cell numbers |
| AU2004282179B2 (en) | 2003-10-14 | 2011-05-19 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein kinase inhibitors |
| US20090029982A1 (en) * | 2005-04-28 | 2009-01-29 | Supergen, Inc. | Protein kinase inhibitors |
| ATE478863T1 (de) | 2005-07-14 | 2010-09-15 | Irm Llc | Heterotetracyclische verbindungen als tpo- mimetica |
| EP1749822B1 (en) * | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| US7816542B2 (en) | 2005-08-15 | 2010-10-19 | Irm Llc | Compounds and compositions as TPO mimetics |
| KR20090021217A (ko) | 2006-06-14 | 2009-02-27 | 추가이 세이야쿠 가부시키가이샤 | 조혈 줄기세포 증가 촉진제 |
| JP2008050355A (ja) * | 2006-08-21 | 2008-03-06 | Eisai R & D Management Co Ltd | 造血幹細胞を増殖、分化および／または循環系内に動員させる医薬組成物および方法 |
| WO2008028645A1 (en) | 2006-09-05 | 2008-03-13 | Aplagen Gmbh | Peptides binding the tpo receptor |
| WO2008055233A1 (en) | 2006-10-31 | 2008-05-08 | Supergen, Inc. | Protein kinase inhibitors |
| US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| EP2121692B1 (en) * | 2006-12-22 | 2013-04-10 | Incyte Corporation | Substituted heterocycles as janus kinase inhibitors |
| JP2010525836A (ja) * | 2007-05-04 | 2010-07-29 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | ヒト造血幹細胞のｅｘｖｉｖｏ増殖 |
| EP2170886A1 (en) | 2007-07-02 | 2010-04-07 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
| US7982035B2 (en) * | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| JP2010193879A (ja) | 2009-01-27 | 2010-09-09 | Jms Co Ltd | 臍帯血造血幹細胞の増殖制御方法およびその用途 |
| WO2011056739A1 (en) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Compounds and methods |
| US9732083B2 (en) | 2011-03-15 | 2017-08-15 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
| PT2807165T (pt) | 2012-01-27 | 2019-07-12 | Univ Montreal | Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas |
-
2013
- 2013-01-25 PT PT13740815T patent/PT2807165T/pt unknown
- 2013-01-25 EP EP13740815.9A patent/EP2807165B1/en active Active
- 2013-01-25 ES ES13740815T patent/ES2733946T3/es active Active
- 2013-01-25 AU AU2013212457A patent/AU2013212457B2/en active Active
- 2013-01-25 CN CN201380007006.5A patent/CN104144931B/zh active Active
- 2013-01-25 WO PCT/CA2013/050052 patent/WO2013110198A1/en not_active Ceased
- 2013-01-25 NZ NZ627188A patent/NZ627188A/en unknown
- 2013-01-25 SM SM20190360T patent/SMT201900360T1/it unknown
- 2013-01-25 HU HUE13740815A patent/HUE044070T4/hu unknown
- 2013-01-25 HR HRP20191189TT patent/HRP20191189T1/hr unknown
- 2013-01-25 SI SI201331486T patent/SI2807165T1/sl unknown
- 2013-01-25 JP JP2014553589A patent/JP6250556B2/ja active Active
- 2013-01-25 BR BR112014018524-7A patent/BR112014018524B1/pt active IP Right Grant
- 2013-01-25 SG SG11201404241SA patent/SG11201404241SA/en unknown
- 2013-01-25 LT LTEP13740815.9T patent/LT2807165T/lt unknown
- 2013-01-25 RS RS20190858A patent/RS59002B1/sr unknown
- 2013-01-25 KR KR1020147023818A patent/KR102098122B1/ko active Active
- 2013-01-25 PL PL13740815T patent/PL2807165T3/pl unknown
- 2013-01-25 TR TR2019/09582T patent/TR201909582T4/tr unknown
- 2013-01-25 DK DK13740815.9T patent/DK2807165T3/da active
- 2013-01-25 CA CA2862140A patent/CA2862140C/en active Active
- 2013-01-25 US US14/374,953 patent/US9409906B2/en active Active
-
2014
- 2014-07-10 IL IL23358714A patent/IL233587B/en active IP Right Grant
-
2016
- 2016-02-18 US US15/047,292 patent/US20160222017A1/en not_active Abandoned
- 2016-12-02 US US15/368,082 patent/US10336747B2/en active Active
-
2019
- 2019-07-05 CY CY20191100713T patent/CY1121799T1/el unknown
-
2026
- 2026-01-14 FR FR26C1003C patent/FR26C1003I1/fr active Active
- 2026-01-19 LT LTPA2026503C patent/LTPA2026503I1/lt unknown
- 2026-01-21 NL NL301363C patent/NL301363I2/nl unknown
- 2026-01-21 NO NO2026005C patent/NO2026005I1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504902A5 (https=) | ||
| JP2017513897A5 (https=) | ||
| HRP20191189T1 (hr) | Pirimido[4,5-b]indol derivati i njihova primjena u ekspanziji hematopoetskih matičnih stanica | |
| JP2023171766A5 (https=) | ||
| Yao et al. | Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15 | |
| AU2018253115B2 (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| RU2422513C2 (ru) | Способы экспансии популяций миелоидных клеток и их использование | |
| EP3134409B1 (en) | Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells | |
| Bacigalupo et al. | Haploidentical donor transplants for severe aplastic anemia | |
| JP2017524025A5 (https=) | ||
| FI3406251T3 (fi) | Pyruvaattikinaasin aktivaattoreita terapeuttista käyttöä varten | |
| Bastani et al. | The quest for the holy grail: overcoming challenges in expanding human hematopoietic stem cells for clinical use | |
| Aljagthmi et al. | Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation | |
| US11702635B2 (en) | Hematopoietic stem cell expansion method | |
| JP7467358B2 (ja) | 免疫応答を媒介するｉｎ ｖｉｖｏでのＮＫ細胞およびＤＣ細胞の拡大 | |
| JP2021521262A5 (https=) | ||
| Sakurai et al. | Ex vivo expansion of human hematopoietic stem cells and clinical applications | |
| Choi et al. | Co‑transplantation of tonsil‑derived mesenchymal stromal cells in bone marrow transplantation promotes thymus regeneration and T cell diversity following cytotoxic conditioning | |
| JP2018516089A (ja) | 造血幹細胞を培養するため及び／又は造血幹細胞を前駆体へ分化させるための方法及びその使用 | |
| US12060310B2 (en) | Compositions and methods of using itaconic acid derivatives | |
| Radtke et al. | Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice | |
| JP7477520B2 (ja) | 幹細胞療法 | |
| JP2017520275A5 (https=) | ||
| JPWO2019161494A5 (https=) | ||
| JPWO2024135853A5 (https=) |